

Serial No.: 10/629,976
Filing Date: July 30, 2003

and asserted in the Advisory Action that the present application does not claim domestic priority to the '029 application and to application 09/356, 466. In response to the Final Office Action dated February 9, 2007, Applicants provided evidence showing that continuity in the priority chain exists between the present application and the cited patent. The evidence was discussed during the conversation with the Examiner, and the Examiner acknowledged that a priority claim of parent application serial no. 09/824,827 (US 6,627,744) had been made in the parent application to the '029 application. At the request of the Examiner, Applicants enclose a copy of Applicants' response to the Final Office Action (appendix A).

The Examiner requested that Applicants indicate where the specification of the prior filed application '029 application ('098 patent) provides support for the currently pending claims.

Applicants submit that the '029 application issued as the '098 patent provides support for Claims 1-16 as follows. (a) The '098 patent teaches glycosylated thiosulfonates. (b) Col. 8, lines 34 45 states that "Preferably, the glycosylated thiosulfonate comprises methanethiosulfonate. More preferably, the methanethiosulfonate comprises the chemical structure: H₃CO₂SSR". (c) Col 10, line 67 to Col 11, line 23 states that "By glycosylated is meant that the thiosulfonate has bound thereto a sugar or carbohydrate moiety which can be transferred to a protein pursuant to the present invention. Preferably, the glycosylated thiosulfonates are glycosylated alkylthiosulfonates, most preferably, glycosylated methanethiosulfonates. Such glycosylated methanethiosulfonate have the general formula: H₃CO₂SSR."

In particularly preferred embodiment, the methanethiosulfonate comprises an R group which comprises: β-Glc, -Et- β-Gal, -Et- β-Glc, -Et-α-Glc, -Et-α-Man, -Et-Lac, - β-Glc(Ac).sub.2, - β-Glc(Ac)₃, β-Glc(Ac)₄, -Et-α-Glc(Ac)₂, -Et-α-Glc(Ac).sub.3, -Et-α-Glc(Ac)₄, -Et- β-Glc(Ac)₂, -Et- β-Glc(Ac)₃, -Et-β-Glc(Ac)₄, -Et-α-Man(Ac)₃, -Et-.alpha.-Man(Ac)₄, -Et-β-Gal(Ac)₃, -Et- β-Gal(Ac)₄, -Et-Lac(Ac).sub.5, -Et-Lac(Ac).sub.6, or -Et-Lac(Ac)₇.

In a preferred embodiment, the carbohydrate moiety of the present invention is a dendrimer moiety."

Serial No.: 10/629,976
Filing Date: July 30, 2003

The disclosure as a whole teaches glycodendrimer compositions comprising compounds having varying lengths and sugars. In particular, (a) support for Claim 16 is provided, for example, in Figure 1 of the '098 patent. (b) Dependent Claims 17-19 are supported, for example, by the disclosure cited above; (c) dependent Claim 20 is supported, for example, by Figure 6, (d) dependent Claim 21 is supported, for example, by Figure 8; and (e) dependent Claim 24 is supported, for example, by the specification that discloses compounds comprising glucose, and by Figure 2, which discloses compounds comprising H₃CO₂SS-(CH₂)_a, wherein a=3.


Thus, Applicants submit that the '098 patent supports the claims of the present application within the meaning of 35 U.S.C. § 112, first paragraph.

Pursuant to the telephone conversation the Examiner indicated that he would allow the pending claims upon a showing of support for the pending claims in the '029 application ('098 patent). In light of the foregoing, Applicants submit that the '029 application supports the claims of the present application within the meaning of 35 U.S.C. § 112, first paragraph. Accordingly, Applicants respectfully request the issuance of a formal Notice of Allowance.

The Commissioner is authorized to charge any fees that may be required in connection with this submission and to credit any overpayments to Deposit Account No. 07-1048 (Attorney Docket No. GC541-4-C1).

Respectfully submitted,

Date: June 14, 2007


Elena Quertermous
Elena Quertermous
Registration No. 47,873

Danisco US Inc., Genencor Division
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-7636
Fax: 650-845-6504

GC541-4-C1

Page 3 of 3